nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.129	0.215	CbGbCtD
Tolvaptan—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0872	0.145	CbGbCtD
Tolvaptan—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0832	0.139	CbGbCtD
Tolvaptan—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0741	0.124	CbGbCtD
Tolvaptan—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.0726	0.121	CbGbCtD
Tolvaptan—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.0686	0.114	CbGbCtD
Tolvaptan—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0435	0.0726	CbGbCtD
Tolvaptan—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0411	0.0685	CbGbCtD
Tolvaptan—AVPR1A—respiratory system—chronic obstructive pulmonary disease	0.01	0.333	CbGeAlD
Tolvaptan—AVPR2—respiratory system—chronic obstructive pulmonary disease	0.00832	0.276	CbGeAlD
Tolvaptan—AVPR1A—lung—chronic obstructive pulmonary disease	0.00533	0.177	CbGeAlD
Tolvaptan—Rhabdomyolysis—Aminophylline—chronic obstructive pulmonary disease	0.00458	0.0162	CcSEcCtD
Tolvaptan—AVPR2—lung—chronic obstructive pulmonary disease	0.00442	0.147	CbGeAlD
Tolvaptan—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00439	0.0535	CbGpPWpGaD
Tolvaptan—Hyperuricaemia—Aminophylline—chronic obstructive pulmonary disease	0.00437	0.0155	CcSEcCtD
Tolvaptan—Blood uric acid increased—Aminophylline—chronic obstructive pulmonary disease	0.00413	0.0146	CcSEcCtD
Tolvaptan—Zafirlukast—CYP1A2—chronic obstructive pulmonary disease	0.004	0.672	CrCbGaD
Tolvaptan—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00388	0.0473	CbGpPWpGaD
Tolvaptan—Polyuria—Aminophylline—chronic obstructive pulmonary disease	0.00335	0.0119	CcSEcCtD
Tolvaptan—Hypernatraemia—Prednisolone—chronic obstructive pulmonary disease	0.00318	0.0112	CcSEcCtD
Tolvaptan—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00317	0.0387	CbGpPWpGaD
Tolvaptan—Hyperkalaemia—Arformoterol—chronic obstructive pulmonary disease	0.00303	0.0107	CcSEcCtD
Tolvaptan—Hyperkalaemia—Formoterol—chronic obstructive pulmonary disease	0.00303	0.0107	CcSEcCtD
Tolvaptan—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.003	0.0106	CcSEcCtD
Tolvaptan—AVPR1A—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.0029	0.0353	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00288	0.0351	CbGpPWpGaD
Tolvaptan—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.00283	0.01	CcSEcCtD
Tolvaptan—Immune system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00276	0.00975	CcSEcCtD
Tolvaptan—Mediastinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00275	0.00973	CcSEcCtD
Tolvaptan—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.00266	0.0094	CcSEcCtD
Tolvaptan—Dysgeusia—Roflumilast—chronic obstructive pulmonary disease	0.0026	0.0092	CcSEcCtD
Tolvaptan—AVPR2—Arf6 trafficking events—ADRB2—chronic obstructive pulmonary disease	0.00259	0.0316	CbGpPWpGaD
Tolvaptan—Dehydration—Tiotropium—chronic obstructive pulmonary disease	0.00258	0.00913	CcSEcCtD
Tolvaptan—Ill-defined disorder—Roflumilast—chronic obstructive pulmonary disease	0.00247	0.00872	CcSEcCtD
Tolvaptan—Malaise—Roflumilast—chronic obstructive pulmonary disease	0.0024	0.00847	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.00236	0.0288	CbGpPWpGaD
Tolvaptan—Hypernatraemia—Prednisone—chronic obstructive pulmonary disease	0.00231	0.00817	CcSEcCtD
Tolvaptan—Thirst—Montelukast—chronic obstructive pulmonary disease	0.0023	0.00815	CcSEcCtD
Tolvaptan—Hypoglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.00229	0.00812	CcSEcCtD
Tolvaptan—Hypoglycaemia—Formoterol—chronic obstructive pulmonary disease	0.00229	0.00812	CcSEcCtD
Tolvaptan—Hyperglycaemia—Aminophylline—chronic obstructive pulmonary disease	0.00229	0.00811	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00225	0.00795	CcSEcCtD
Tolvaptan—Discomfort—Roflumilast—chronic obstructive pulmonary disease	0.00223	0.0079	CcSEcCtD
Tolvaptan—Hypoglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00217	0.00766	CcSEcCtD
Tolvaptan—Hyperglycaemia—Tiotropium—chronic obstructive pulmonary disease	0.00216	0.00765	CcSEcCtD
Tolvaptan—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00213	0.00752	CcSEcCtD
Tolvaptan—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.00211	0.00745	CcSEcCtD
Tolvaptan—Renal failure—Tiotropium—chronic obstructive pulmonary disease	0.0021	0.00743	CcSEcCtD
Tolvaptan—Dehydration—Arformoterol—chronic obstructive pulmonary disease	0.00208	0.00737	CcSEcCtD
Tolvaptan—Dehydration—Formoterol—chronic obstructive pulmonary disease	0.00208	0.00737	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.00197	0.00699	CcSEcCtD
Tolvaptan—Vismodegib—ALB—chronic obstructive pulmonary disease	0.00196	0.328	CrCbGaD
Tolvaptan—Alanine aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.00193	0.00684	CcSEcCtD
Tolvaptan—Urinary tract disorder—Tiotropium—chronic obstructive pulmonary disease	0.0019	0.0067	CcSEcCtD
Tolvaptan—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.00189	0.00667	CcSEcCtD
Tolvaptan—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.00188	0.00667	CcSEcCtD
Tolvaptan—Urethral disorder—Tiotropium—chronic obstructive pulmonary disease	0.00188	0.00666	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00187	0.00662	CcSEcCtD
Tolvaptan—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00185	0.00656	CcSEcCtD
Tolvaptan—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00179	0.00632	CcSEcCtD
Tolvaptan—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.00175	0.00617	CcSEcCtD
Tolvaptan—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.00175	0.00617	CcSEcCtD
Tolvaptan—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.00174	0.00616	CcSEcCtD
Tolvaptan—Immune system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00173	0.00613	CcSEcCtD
Tolvaptan—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00173	0.00612	CcSEcCtD
Tolvaptan—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.00167	0.00591	CcSEcCtD
Tolvaptan—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00165	0.00583	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.00162	0.0198	CbGpPWpGaD
Tolvaptan—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00161	0.0196	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.0016	0.00565	CcSEcCtD
Tolvaptan—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00156	0.0055	CcSEcCtD
Tolvaptan—Urinary tract disorder—Arformoterol—chronic obstructive pulmonary disease	0.00153	0.00541	CcSEcCtD
Tolvaptan—Urinary tract disorder—Formoterol—chronic obstructive pulmonary disease	0.00153	0.00541	CcSEcCtD
Tolvaptan—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.00152	0.00538	CcSEcCtD
Tolvaptan—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.00152	0.00538	CcSEcCtD
Tolvaptan—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.00152	0.00537	CcSEcCtD
Tolvaptan—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.00152	0.00537	CcSEcCtD
Tolvaptan—Ecchymosis—Prednisolone—chronic obstructive pulmonary disease	0.00151	0.00534	CcSEcCtD
Tolvaptan—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.0015	0.0053	CcSEcCtD
Tolvaptan—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.0015	0.0053	CcSEcCtD
Tolvaptan—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.00149	0.00527	CcSEcCtD
Tolvaptan—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.00149	0.00526	CcSEcCtD
Tolvaptan—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00148	0.00525	CcSEcCtD
Tolvaptan—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.00147	0.00519	CcSEcCtD
Tolvaptan—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.00145	0.00511	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.00144	0.0176	CbGpPWpGaD
Tolvaptan—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.00144	0.00511	CcSEcCtD
Tolvaptan—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.00144	0.00509	CcSEcCtD
Tolvaptan—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.00144	0.00509	CcSEcCtD
Tolvaptan—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.00144	0.00508	CcSEcCtD
Tolvaptan—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00143	0.00507	CcSEcCtD
Tolvaptan—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.00143	0.00507	CcSEcCtD
Tolvaptan—Shock—Aminophylline—chronic obstructive pulmonary disease	0.00142	0.00503	CcSEcCtD
Tolvaptan—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.00142	0.00502	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00141	0.005	CcSEcCtD
Tolvaptan—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.00141	0.00498	CcSEcCtD
Tolvaptan—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.0014	0.00495	CcSEcCtD
Tolvaptan—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.0014	0.00495	CcSEcCtD
Tolvaptan—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.0014	0.00494	CcSEcCtD
Tolvaptan—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.0014	0.00494	CcSEcCtD
Tolvaptan—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00139	0.00492	CcSEcCtD
Tolvaptan—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.00138	0.00488	CcSEcCtD
Tolvaptan—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.00137	0.00485	CcSEcCtD
Tolvaptan—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00137	0.00484	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.00136	0.0166	CbGpPWpGaD
Tolvaptan—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00136	0.0048	CcSEcCtD
Tolvaptan—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.00136	0.0048	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.00135	0.0165	CbGpPWpGaD
Tolvaptan—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.00135	0.00477	CcSEcCtD
Tolvaptan—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.00135	0.00477	CcSEcCtD
Tolvaptan—Shock—Tiotropium—chronic obstructive pulmonary disease	0.00134	0.00475	CcSEcCtD
Tolvaptan—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00134	0.00473	CcSEcCtD
Tolvaptan—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00133	0.00469	CcSEcCtD
Tolvaptan—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00132	0.00469	CcSEcCtD
Tolvaptan—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00132	0.00467	CcSEcCtD
Tolvaptan—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.00132	0.00467	CcSEcCtD
Tolvaptan—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.00132	0.00467	CcSEcCtD
Tolvaptan—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00132	0.00466	CcSEcCtD
Tolvaptan—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00129	0.00456	CcSEcCtD
Tolvaptan—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.00127	0.0045	CcSEcCtD
Tolvaptan—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00126	0.00445	CcSEcCtD
Tolvaptan—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.00125	0.00443	CcSEcCtD
Tolvaptan—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.00125	0.00443	CcSEcCtD
Tolvaptan—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.00441	CcSEcCtD
Tolvaptan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.00123	0.0151	CbGpPWpGaD
Tolvaptan—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00122	0.0043	CcSEcCtD
Tolvaptan—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00122	0.0043	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	0.00119	0.0146	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00118	0.00418	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00118	0.00416	CcSEcCtD
Tolvaptan—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00117	0.00412	CcSEcCtD
Tolvaptan—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00115	0.00406	CcSEcCtD
Tolvaptan—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00114	0.00404	CcSEcCtD
Tolvaptan—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.00114	0.00404	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00114	0.00403	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.00403	CcSEcCtD
Tolvaptan—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00113	0.00401	CcSEcCtD
Tolvaptan—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00113	0.00401	CcSEcCtD
Tolvaptan—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00112	0.00397	CcSEcCtD
Tolvaptan—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00112	0.00397	CcSEcCtD
Tolvaptan—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00396	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00112	0.00395	CcSEcCtD
Tolvaptan—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.0011	0.00389	CcSEcCtD
Tolvaptan—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.0011	0.00389	CcSEcCtD
Tolvaptan—Ecchymosis—Prednisone—chronic obstructive pulmonary disease	0.0011	0.00388	CcSEcCtD
Tolvaptan—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00108	0.00382	CcSEcCtD
Tolvaptan—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00108	0.00382	CcSEcCtD
Tolvaptan—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00108	0.00381	CcSEcCtD
Tolvaptan—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00379	CcSEcCtD
Tolvaptan—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00107	0.00378	CcSEcCtD
Tolvaptan—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00107	0.00378	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.00107	0.013	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00107	0.00377	CcSEcCtD
Tolvaptan—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00106	0.00375	CcSEcCtD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.00106	0.0129	CbGpPWpGaD
Tolvaptan—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00106	0.00374	CcSEcCtD
Tolvaptan—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00105	0.0037	CcSEcCtD
Tolvaptan—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00368	CcSEcCtD
Tolvaptan—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00102	0.00362	CcSEcCtD
Tolvaptan—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00102	0.00362	CcSEcCtD
Tolvaptan—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00102	0.0036	CcSEcCtD
Tolvaptan—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00101	0.00357	CcSEcCtD
Tolvaptan—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.001	0.00355	CcSEcCtD
Tolvaptan—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00099	0.0035	CcSEcCtD
Tolvaptan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000989	0.0035	CcSEcCtD
Tolvaptan—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000965	0.00341	CcSEcCtD
Tolvaptan—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000957	0.0117	CbGpPWpGaD
Tolvaptan—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000956	0.00338	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00095	0.00336	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00095	0.00336	CcSEcCtD
Tolvaptan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000941	0.00333	CcSEcCtD
Tolvaptan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000941	0.00333	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000931	0.00329	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000914	0.0111	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000907	0.0111	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000907	0.00321	CcSEcCtD
Tolvaptan—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000907	0.00321	CcSEcCtD
Tolvaptan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000906	0.0032	CcSEcCtD
Tolvaptan—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000903	0.0032	CcSEcCtD
Tolvaptan—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000902	0.00319	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000897	0.00317	CcSEcCtD
Tolvaptan—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000897	0.0297	CbGeAlD
Tolvaptan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000889	0.00314	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000881	0.00312	CcSEcCtD
Tolvaptan—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.00087	0.00308	CcSEcCtD
Tolvaptan—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.00087	0.00308	CcSEcCtD
Tolvaptan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000859	0.00304	CcSEcCtD
Tolvaptan—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000856	0.00303	CcSEcCtD
Tolvaptan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000854	0.00302	CcSEcCtD
Tolvaptan—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000852	0.00301	CcSEcCtD
Tolvaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000831	0.0101	CbGpPWpGaD
Tolvaptan—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000821	0.00291	CcSEcCtD
Tolvaptan—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000811	0.00287	CcSEcCtD
Tolvaptan—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000811	0.00287	CcSEcCtD
Tolvaptan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00081	0.00287	CcSEcCtD
Tolvaptan—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000794	0.00281	CcSEcCtD
Tolvaptan—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.00079	0.00279	CcSEcCtD
Tolvaptan—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.00079	0.00279	CcSEcCtD
Tolvaptan—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000779	0.00275	CcSEcCtD
Tolvaptan—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000779	0.00275	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000777	0.00275	CcSEcCtD
Tolvaptan—AVPR1A—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000773	0.00944	CbGpPWpGaD
Tolvaptan—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000773	0.00274	CcSEcCtD
Tolvaptan—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000766	0.00271	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000764	0.00932	CbGpPWpGaD
Tolvaptan—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000763	0.0027	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000758	0.00925	CbGpPWpGaD
Tolvaptan—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000756	0.00922	CbGpPWpGaD
Tolvaptan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000753	0.00266	CcSEcCtD
Tolvaptan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000753	0.00266	CcSEcCtD
Tolvaptan—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000746	0.00264	CcSEcCtD
Tolvaptan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000738	0.009	CbGpPWpGaD
Tolvaptan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000738	0.00261	CcSEcCtD
Tolvaptan—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000735	0.0026	CcSEcCtD
Tolvaptan—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000728	0.00257	CcSEcCtD
Tolvaptan—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000728	0.00257	CcSEcCtD
Tolvaptan—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000724	0.00883	CbGpPWpGaD
Tolvaptan—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000713	0.00252	CcSEcCtD
Tolvaptan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000711	0.00251	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000696	0.00849	CbGpPWpGaD
Tolvaptan—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000695	0.00848	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000692	0.00844	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000691	0.00843	CbGpPWpGaD
Tolvaptan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000689	0.00244	CcSEcCtD
Tolvaptan—Headache—Formoterol—chronic obstructive pulmonary disease	0.000689	0.00244	CcSEcCtD
Tolvaptan—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000687	0.00243	CcSEcCtD
Tolvaptan—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000687	0.00243	CcSEcCtD
Tolvaptan—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000678	0.0024	CcSEcCtD
Tolvaptan—AVPR1A—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000677	0.00826	CbGpPWpGaD
Tolvaptan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000675	0.00239	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000669	0.00816	CbGpPWpGaD
Tolvaptan—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000668	0.00815	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000664	0.0081	CbGpPWpGaD
Tolvaptan—ABCB1—trachea—chronic obstructive pulmonary disease	0.000663	0.022	CbGeAlD
Tolvaptan—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000659	0.00233	CcSEcCtD
Tolvaptan—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000655	0.00232	CcSEcCtD
Tolvaptan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000654	0.00231	CcSEcCtD
Tolvaptan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000654	0.00231	CcSEcCtD
Tolvaptan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000651	0.0023	CcSEcCtD
Tolvaptan—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000642	0.00227	CcSEcCtD
Tolvaptan—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00064	0.00226	CcSEcCtD
Tolvaptan—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000617	0.00218	CcSEcCtD
Tolvaptan—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000614	0.00217	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000605	0.00738	CbGpPWpGaD
Tolvaptan—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000604	0.00736	CbGpPWpGaD
Tolvaptan—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000599	0.00212	CcSEcCtD
Tolvaptan—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000596	0.00211	CcSEcCtD
Tolvaptan—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000586	0.00207	CcSEcCtD
Tolvaptan—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00058	0.00707	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000573	0.00699	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.00057	0.00695	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000569	0.00694	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000566	0.0069	CbGpPWpGaD
Tolvaptan—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000553	0.00196	CcSEcCtD
Tolvaptan—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000551	0.00195	CcSEcCtD
Tolvaptan—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000549	0.0067	CbGpPWpGaD
Tolvaptan—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000531	0.00188	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000523	0.00638	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000519	0.00634	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000512	0.00625	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000509	0.0062	CbGpPWpGaD
Tolvaptan—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000505	0.00616	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000492	0.00174	CcSEcCtD
Tolvaptan—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000491	0.00174	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000488	0.00595	CbGpPWpGaD
Tolvaptan—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000486	0.00592	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000484	0.00591	CbGpPWpGaD
Tolvaptan—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000479	0.00169	CcSEcCtD
Tolvaptan—ABCB1—lung—chronic obstructive pulmonary disease	0.000476	0.0158	CbGeAlD
Tolvaptan—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000476	0.00168	CcSEcCtD
Tolvaptan—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000466	0.00165	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000461	0.00562	CbGpPWpGaD
Tolvaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000455	0.00555	CbGpPWpGaD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000449	0.00159	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000448	0.00547	CbGpPWpGaD
Tolvaptan—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000446	0.00158	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000445	0.00543	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000443	0.00541	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.00044	0.00537	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000439	0.00155	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000437	0.00533	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000433	0.00529	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000433	0.00153	CcSEcCtD
Tolvaptan—Shock—Prednisone—chronic obstructive pulmonary disease	0.000426	0.00151	CcSEcCtD
Tolvaptan—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000425	0.0015	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000424	0.00517	CbGpPWpGaD
Tolvaptan—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000421	0.00149	CcSEcCtD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.00042	0.00512	CbGpPWpGaD
Tolvaptan—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000413	0.00146	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000413	0.00504	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.00041	0.005	CbGpPWpGaD
Tolvaptan—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000394	0.00139	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000393	0.0048	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.00039	0.00476	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.00039	0.00476	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000387	0.00473	CbGpPWpGaD
Tolvaptan—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000376	0.00133	CcSEcCtD
Tolvaptan—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000373	0.00132	CcSEcCtD
Tolvaptan—Constipation—Prednisone—chronic obstructive pulmonary disease	0.00037	0.00131	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000357	0.00436	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000357	0.00436	CbGpPWpGaD
Tolvaptan—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000357	0.00435	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000357	0.00126	CcSEcCtD
Tolvaptan—AVPR2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000355	0.00433	CbGpPWpGaD
Tolvaptan—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000354	0.00125	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000345	0.00421	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000343	0.00418	CbGpPWpGaD
Tolvaptan—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000342	0.00121	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000341	0.00416	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000339	0.00413	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000337	0.00411	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000319	0.00113	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000318	0.00388	CbGpPWpGaD
Tolvaptan—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000311	0.0011	CcSEcCtD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000309	0.00377	CbGpPWpGaD
Tolvaptan—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000306	0.00108	CcSEcCtD
Tolvaptan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000296	0.00105	CcSEcCtD
Tolvaptan—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000295	0.0036	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000289	0.00352	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000288	0.00351	CbGpPWpGaD
Tolvaptan—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000286	0.00101	CcSEcCtD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000285	0.00347	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000277	0.00338	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000275	0.00336	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000275	0.00335	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000274	0.00334	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000273	0.00333	CbGpPWpGaD
Tolvaptan—Headache—Prednisone—chronic obstructive pulmonary disease	0.000271	0.00096	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000262	0.00319	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.00026	0.00317	CbGpPWpGaD
Tolvaptan—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000259	0.00316	CbGpPWpGaD
Tolvaptan—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000257	0.00091	CcSEcCtD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000255	0.00311	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000247	0.00301	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000245	0.00299	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000234	0.00285	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000224	0.00273	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000222	0.00271	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.00022	0.00269	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000219	0.00267	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000215	0.00262	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000211	0.00257	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000211	0.00257	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.00021	0.00256	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.00021	0.00256	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000209	0.00256	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000209	0.00255	CbGpPWpGaD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000207	0.00252	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.0002	0.00244	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000199	0.00242	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000193	0.00235	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000191	0.00234	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	0.000191	0.00233	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000175	0.00214	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000174	0.00212	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00017	0.00207	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.000158	0.00192	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000154	0.00188	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000153	0.00187	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000151	0.00184	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.00015	0.00182	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000148	0.0018	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	0.000148	0.0018	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000143	0.00175	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000142	0.00174	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000132	0.00161	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000131	0.0016	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.000128	0.00156	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000124	0.00152	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000123	0.0015	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000119	0.00145	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000118	0.00144	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000118	0.00144	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	0.000118	0.00144	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.000117	0.00143	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000117	0.00143	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.00011	0.00134	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000108	0.00132	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000107	0.00131	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.000107	0.00131	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000107	0.0013	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000104	0.00126	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000103	0.00126	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000103	0.00125	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000102	0.00125	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.62e-05	0.00117	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.55e-05	0.00116	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	9.52e-05	0.00116	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	9.39e-05	0.00115	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	9.03e-05	0.0011	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	8.91e-05	0.00109	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.91e-05	0.000965	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.85e-05	0.000958	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.81e-05	0.000953	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	7.6e-05	0.000927	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.55e-05	0.000921	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.49e-05	0.000914	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	7.26e-05	0.000886	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.21e-05	0.000879	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.15e-05	0.000873	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.06e-05	0.000862	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.39e-05	0.00078	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.35e-05	0.000774	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	6.31e-05	0.00077	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.08e-05	0.000741	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	6.06e-05	0.000739	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.03e-05	0.000736	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	5.79e-05	0.000707	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.78e-05	0.000705	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.74e-05	0.0007	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	5.68e-05	0.000693	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	5.41e-05	0.00066	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.19e-05	0.000633	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.15e-05	0.000629	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.81e-05	0.000587	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	4.77e-05	0.000582	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.76e-05	0.000581	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.73e-05	0.000577	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	4.68e-05	0.000571	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.67e-05	0.00057	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.64e-05	0.000566	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.35e-05	0.000531	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.15e-05	0.000506	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	4.1e-05	0.000501	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.92e-05	0.000479	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.89e-05	0.000475	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	3.74e-05	0.000457	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.64e-05	0.000444	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.59e-05	0.000438	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.56e-05	0.000435	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.45e-05	0.000421	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.88e-05	0.000351	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.84e-05	0.000346	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.64e-05	0.000323	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.56e-05	0.000312	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	2.53e-05	0.000308	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.51e-05	0.000306	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.31e-05	0.000281	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.13e-05	0.000259	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.77e-05	0.000216	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.75e-05	0.000213	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	1.7e-05	0.000208	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.63e-05	0.000199	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.63e-05	0.000199	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.54e-05	0.000188	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.05e-05	0.000128	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1e-05	0.000122	CbGpPWpGaD
